芪苈强心胶囊联合曲美他嗪对冠心病心力衰竭患者左心室重构及血清NT-proBNP、CK-MB、cTnI水平的影响

Effects of Qili qiangxin capsule combined with trimetazidine on left ventricular remodeling and serum NT-proBNP,CK-MB,cTnI levels in patients with coronary heart disease and heart failure

目的探讨芪苈强心胶囊联合曲美他嗪对冠心病心力衰竭患者左心室重构及血清NT-proBNP、CK-MB、cTnI水平的影响。方法选取2019年2月~2020年2月乌鲁木齐市友谊医院心血管内科收治的90例冠心病心力衰竭患者,通过随机数字表法将其分为治疗组、对照组,各45例。对照组给予盐酸曲美他嗪片进行治疗,治疗组在对照组的基础上给予芪苈强心胶囊进行治疗,两组均治疗3个月。比较两组治疗3个月后的临床疗效;对比两组治疗前、治疗3个月后的中医症候积分、左心室重构指标及神经内分泌指标水平。结果治疗3个月后,两组疗效比较,治疗组高于对照组(93.33%vs 73.33%,P<0.05)。与治疗前比较,治疗3个月后,两组中医证候积分、LVESV、LVEDV、血清NT-proBNP、CK-MB、cTnI水平均降低,且治疗组均低于对照组(P<0.05);两组LVEF均升高,且治疗组高于对照组(P<0.05)。结论芪苈强心胶囊联合曲美他嗪治疗冠心病心力衰竭,可明显降低患者血清NT-proBNP、CK-MB、cTnI水平,改善左心室重构,进而有助于提高疗效。

Objective To investigate the effects of Qili qiangxin capsule combined with trimetazidine on left ventricular remodeling and serum NT-pro BNP,CK-MB,cTnI levels in patients with coronary heart disease and heart failure.Methods 90 patients with coronary heart disease and heart failure admitted to department of cardiovascular medicine,Urumqi friendship hospital from February 2019 to February 2020 were selected and divided into the treatment group and control group by a random number table method,with 45 cases in each group.The control group was treated with trimetazidine hydrochloride tablets,and the observation group was given Qili qiangxin capsules on the basis of the control group,both groups were treated for 3 months.The clinical efficacy in the two groups after 3 months of treatment was compared;the score of TCM symptoms,the levels of left ventricular remodeling indicators and neuroendocrine indicators after 3 months of treatment were compared.Results After 3 months of treatment,comparison of efficacy between the two groups,the treatment group was higher than the control group(93.33%vs 73.33%,P<0.05).Compared with before treatment,after 3 months of treatment,the scores of TCM syndrome,the LVESV,LVEDV,the levels of serum NT-pro BNP,CK-MB,cTnI in the two groups decreased,and all in the treatment group were lower than the control group(P<0.05);the LVEF increased in both groups,and the treatment group was higher than the control group(P<0.05).Conclusion Qili qiangxin capsule combined with trimetazidine in the treatment of coronary heart disease and heart failure can significantly reduce the levels of serum NT-pro BNP,CK-MB and cTnI,improve left ventricular remodeling,and thus help to improve the efficacy.